Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Smarter staging for endometrial cancer: Researchers at UCLouvain in Belgium have developed a practical algorithm that goes beyond traditional TNM staging to guide adjuvant therapy decisions using molecular tumor profiles. The tool stratifies early-stage patients into four risk groups — from low risk (no treatment needed) to high risk (chemoradiotherapy) — and is designed to slot directly into multidisciplinary team meetings. It's an operational translation of the 2025 ESGO/ESTRO/ESP guidelines.
Smarter staging for endometrial cancer
Clinicians managing endometrial cancer after surgery have long relied on TNM staging, tumor grade, and histologic subtype to decide on adjuvant therapy — but that approach is increasingly seen as insufficient. A team at UCLouvain's Cliniques universitaires Saint-Luc in Brussels has developed a practical decision algorithm that incorporates molecular tumor profiling, now recognized by the FIGO 2023 staging system as a key prognostic tool.
The algorithm divides early-stage patients into four risk groups based on recurrence probability and molecular subtype, each with a corresponding treatment strategy. It's designed as an operational translation of the 2025 ESGO/ESTRO/ESP guidelines, built to fit directly into routine multidisciplinary team meetings.
Key Takeaways
Why it matters: Nearly half of high-risk patients still relapse despite standard chemoradiotherapy, making precision risk stratification critical. This algorithm gives clinicians a structured, evidence-based visual tool to navigate increasingly complex treatment decisions at the bedside.
